摘要
目的:观察肺癌肿瘤抑制物1(tumor suppressor in lung cancer 1,TSLC1)在急性白血病(acute leukemia,AL)患者骨髓细胞中的表达情况,探讨其在AL的早期诊断、预后评估及指导治疗中的意义。方法:应用半定量逆转录-聚合酶链反应检测39例AL患者及10例对照组骨髓细胞中TSLC1 mRNA的表达情况。结果:对照组TSLC1表达阳性率为80.00%,AL组为12.82%,两组差异有统计学意义(P〈0.01)。急性髓细胞白血病(acute myeloid leukemia,AML)中M1、M2及M5型与对照组TSLC1表达差异均有统计学意义(P〈0.05-P〈0.01);M3、M4型与对照组TSLC1表达差异均无统计学意义(P〉0.05),各亚型间比较差异均无统计学意义(P〉0.05)。结论:AL中TSLC1失表达是一个频发事件,可能与AL的发生、发展有关,对AL的早期诊断、预后评估及指导治疗具有重要意义。
Objective:To determine the expression of tumor suppressor in lung cancer 1 (TSLC1) in the bone marrow cells (BMC) of patients with acute leukemia ( AL), and to evaluate its significance in early diagnosis, prognosis and treatment of AL. Methods : Expression of TSLC1 mRNA in the BMC of 39 AL patients and 10 normal subjects was determined by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). Results:The positive expression of TSLC1 was 80.00 % in the control group, while it was 12.82% in the AL group. The difference was significant ( P 〈 0.01 ). The difference of M1, M2 and M5 in the acute myeloid leukemia (AML) group and the TSLC1 in the control group had statistical significance (P 〈 0.05 -P 〈 0.01 ) ;the difference of M3 and M4 in AML group and the expression of TSLC1 in the control group showed no statistical significance ( P 〉 0.05 ) ; the subtype comparison was not statistically different (P 〉 0.05 ). Conclusions:The loss expression of TSLC1 in AL is a frequent event, which is likely to be correlated with the genesis and progress of AL,and may be of great value in the early diagnosis,prognosis and treatment of AL.
出处
《蚌埠医学院学报》
CAS
2009年第10期868-870,共3页
Journal of Bengbu Medical College
基金
安徽省教育厅自然科学研究资助项目(2006kj396B)
关键词
白血病
基因表达调控
肺癌肿瘤抑制物1
半定量逆转录-聚合酶链反应
leukemia
gene expression regulation
tumor suppressor in lung cancer 1
reverse transcription-polymerase chain reaction